Literature DB >> 7692723

Intravenous pentazocine and methylphenidate abuse during pregnancy. Maternal lifestyle and infant outcome.

V D Debooy1, M M Seshia, M Tenenbein, O G Casiro.   

Abstract

OBJECTIVE: To report the effects of intravenous abuse of pentazocine hydrochloride and methylphenidate hydrochloride during pregnancy.
DESIGN: Retrospective chart review. PATIENTS: All pregnant women and their offspring, whose hospital records indicated prenatal abuse of pentazocine and methylphenidate during the 2-year study period.
RESULTS: The median for maternal age was 22 years and the median number of prenatal visits was two. Twenty mothers had sexually transmitted diseases, 27 abused alcohol, 10 abused other drugs, and all smoked cigarettes. Eight infants were premature, and 12 were growth retarded. Four infants had congenital anomalies: fetal alcohol syndrome (two [twins]), structural heart defect (one), and polydactyly (one). Eleven infants were treated for neonatal abstinence syndrome. Seventeen infants had normal developmental quotients, and four had low-normal developmental quotients.
CONCLUSIONS: Intrauterine exposure to pentazocine and methylphenidate appears to be associated with prematurity, growth retardation, and signs of neonatal withdrawal, but not with any particular teratogenic anomaly or severe developmental delay.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7692723     DOI: 10.1001/archpedi.1993.02160340048012

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  9 in total

1.  The use of central nervous system active drugs during pregnancy.

Authors:  Bengt Källén; Natalia Borg; Margareta Reis
Journal:  Pharmaceuticals (Basel)       Date:  2013-10-10

Review 2.  ADHD treatment and pregnancy.

Authors:  Frank M C Besag
Journal:  Drug Saf       Date:  2014-06       Impact factor: 5.606

3.  Neonatal methylphenidate does not impair adult spatial learning in the Morris water maze in rats.

Authors:  Robyn M Amos-Kroohs; Michael T Williams; Charles V Vorhees
Journal:  Neurosci Lett       Date:  2011-07-20       Impact factor: 3.046

4.  Comparison of monoamine and corticosterone levels 24 h following (+)methamphetamine, (+/-)3,4-methylenedioxymethamphetamine, cocaine, (+)fenfluramine or (+/-)methylphenidate administration in the neonatal rat.

Authors:  Tori L Schaefer; Lisa A Ehrman; Gary A Gudelsky; Charles V Vorhees; Michael T Williams
Journal:  J Neurochem       Date:  2006-09       Impact factor: 5.372

Review 5.  Exposure to attention deficit hyperactivity disorder medications during pregnancy.

Authors:  Caitlin Humphreys; Facundo Garcia-Bournissen; Shinya Ito; Gideon Koren
Journal:  Can Fam Physician       Date:  2007-07       Impact factor: 3.275

Review 6.  Methylphenidate use in pregnancy and lactation: a systematic review of evidence.

Authors:  Blanca M Bolea-Alamanac; Amy Green; Gauri Verma; Penelope Maxwell; Simon J C Davies
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

Review 7.  Pharmacological Treatment of Attention Deficit Hyperactivity Disorder During Pregnancy and Lactation.

Authors:  Asher Ornoy
Journal:  Pharm Res       Date:  2018-02-06       Impact factor: 4.200

Review 8.  The Effects of Drugs used for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) on Pregnancy Outcome and Breast-feeding: A Critical Review.

Authors:  Asher Ornoy; Gideon Koren
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

9.  Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy.

Authors:  Søren Pauli Bro; Maiken Ina Siegismund Kjaersgaard; Erik Thorlund Parner; Merete Juul Sørensen; Jørn Olsen; Bodil Hammer Bech; Lars Henning Pedersen; Jakob Christensen; Mogens Vestergaard
Journal:  Clin Epidemiol       Date:  2015-01-29       Impact factor: 4.790

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.